Literature DB >> 10215288

Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy.

J J Kim1, C W Lee, S W Park, M K Hong, H Y Lim, J K Song, Y S Jin, S J Park.   

Abstract

Transcoronary alcohol ablation (TAA) therapy of septal hypertrophy was recently proposed as a therapeutic modality for obstructive hypertrophic cardiomyopathy (HC). However, questions remain about the effect of TAA on exercise performance. We performed a time-course analysis of exercise capacity and exercise hemodynamics in 20 patients with symptomatic obstructive HC after TAA. Symptom-limited bicycle exercise testing was performed before and 3 and 12 months after TAA, and cardiac catheterization at 3-month follow-up. The pressure gradient of the left ventricular outflow tract immediately decreased from 58 +/- 8 to 4 +/- 1 mm Hg at rest (p <0.01) and from 143 +/- 11 to 30 +/- 6 mm Hg after extrasystole (p <0.01), but partially recovered at 3-month follow-up (14 +/- 4 and 40 +/- 9 mm Hg, respectively). Left ventricular end-diastolic pressure was not changed after TAA. Peak oxygen consumption increased from 19 +/- 2 to 23 +/- 1 ml/kg/min (p < 0.01) and exercise duration from 573 +/- 47 to 742 +/- 46 seconds (p <0.01) at 3-month follow-up, but thereafter reached a plateau. Abnormal patterns of exercise blood pressure response were shown in 9 patients but normalized after TAA. Major complications occurred in 4 patients: no reflow to the left anterior descending coronary artery in 2 patients and ventricular tachycardia requiring cardioversion in 2 patients. During the follow-up period, all patients survived with symptomatic improvement in 17 patients. Thus, TAA is a promising therapeutic modality with improvement in exercise capacity and abnormal exercise blood pressure response in obstructive HC. However, potential serious complications should be considered in the application of TAA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10215288     DOI: 10.1016/s0002-9149(99)00063-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy.

Authors:  Michael P Frenneaux
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

2.  Incidence of Atrial Fibrillation following Alcohol Septal Ablation for Hypertrophic Cardiomyopathy.

Authors:  Travis J Moss; Matthew M Zipse; Mori J Krantz; William H Sauer; Ernesto E Salcedo; Joseph L Schuller
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-03-11       Impact factor: 1.468

3.  Abnormal blood-pressure response to exercise and oxygen consumption in patients with hypertrophic cardiomyopathy.

Authors:  Quirino Ciampi; Sandro Betocchi; Maria Angela Losi; Adele Ferro; Alberto Cuocolo; Raffaella Lombardi; Bruno Villari; Massimo Chiariello
Journal:  J Nucl Cardiol       Date:  2007-10-22       Impact factor: 5.952

Review 4.  Percutaneous transluminal septal myocardial ablation.

Authors:  D N Rubin; E M Tuzcu; H M Lever
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 3.955

5.  Prognostic Significance of Initial r-Wave in Leads V1 and aVR Before PTSMA in Patients with Hypertrophic Obstructive Cardiomyopathy.

Authors:  Xiaowei Jiang; Shubin Qiao
Journal:  Int J Gen Med       Date:  2021-12-10

6.  Percutaneous transluminal radiofrequency closure of the coronary artery in animal studies.

Authors:  Chenyun Zhang; Wei Yi; Yunchang Cai; Shounian Fang; Xinan Jiang; Anzhi Wen; Qiang Wu
Journal:  Exp Ther Med       Date:  2013-08-16       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.